X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6537) 6537
Publication (759) 759
Newspaper Article (348) 348
Book Review (191) 191
Newsletter (49) 49
Magazine Article (33) 33
Book Chapter (16) 16
Trade Publication Article (13) 13
Book / eBook (12) 12
Conference Proceeding (10) 10
Transcript (8) 8
Dissertation (7) 7
Reference (4) 4
Data Set (2) 2
Report (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5296) 5296
index medicus (3987) 3987
oncology (2881) 2881
imatinib mesylate (2522) 2522
male (2261) 2261
female (2228) 2228
middle aged (1773) 1773
benzamides (1706) 1706
cancer (1645) 1645
adult (1597) 1597
pyrimidines - administration & dosage (1506) 1506
hematology (1494) 1494
antineoplastic agents - administration & dosage (1482) 1482
imatinib (1462) 1462
aged (1426) 1426
piperazines - administration & dosage (1304) 1304
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1298) 1298
treatment outcome (1288) 1288
animals (1285) 1285
research (1195) 1195
antineoplastic agents - therapeutic use (1171) 1171
dose-response relationship, drug (1096) 1096
care and treatment (1073) 1073
chronic myelogenous leukemia (1067) 1067
chemotherapy (1037) 1037
dosage and administration (1007) 1007
drug dosages (1004) 1004
chronic myeloid leukemia (987) 987
leukemia (976) 976
drug therapy (964) 964
chronic myeloid-leukemia (962) 962
pyrimidines - therapeutic use (953) 953
pharmacology & pharmacy (922) 922
piperazines - therapeutic use (824) 824
protein kinase inhibitors - administration & dosage (768) 768
tumors (750) 750
therapy (733) 733
antineoplastic combined chemotherapy protocols - therapeutic use (715) 715
antineoplastic agents (712) 712
protein kinase inhibitors - therapeutic use (707) 707
antineoplastic agents - adverse effects (673) 673
mice (673) 673
antimitotic agents (658) 658
health aspects (658) 658
mutation (657) 657
cell line, tumor (653) 653
dasatinib (653) 653
tyrosine kinase inhibitor (616) 616
antineoplastic agents - pharmacology (613) 613
apoptosis (581) 581
kinases (581) 581
cancer therapies (578) 578
pyrimidines - adverse effects (554) 554
aged, 80 and over (548) 548
pyrimidines - pharmacology (536) 536
patients (529) 529
bcr-abl (522) 522
adolescent (520) 520
clinical trials (519) 519
analysis (498) 498
protein-tyrosine kinases - antagonists & inhibitors (489) 489
hemic and lymphatic diseases (477) 477
tyrosine (474) 474
neoplasms - drug therapy (471) 471
prognosis (454) 454
young adult (450) 450
leukemia, myelogenous, chronic, bcr-abl positive - genetics (446) 446
drug resistance, neoplasm (439) 439
piperazines - adverse effects (439) 439
piperazines - pharmacology (439) 439
medicine & public health (436) 436
cell proliferation - drug effects (434) 434
protein kinase inhibitors - pharmacology (434) 434
medicine (433) 433
apoptosis - drug effects (427) 427
proteins (427) 427
disease-free survival (420) 420
risk factors (416) 416
resistance (413) 413
metastasis (411) 411
genetic aspects (410) 410
tyrosine kinase (410) 410
gastrointestinal stromal tumors - drug therapy (408) 408
leukemia, myelogenous, chronic, bcr-abl positive - pathology (405) 405
mesylate (399) 399
time factors (386) 386
fusion proteins, bcr-abl - genetics (382) 382
studies (381) 381
article (379) 379
diagnosis (379) 379
tyrosine kinase inhibitors (376) 376
drug administration schedule (373) 373
nilotinib (370) 370
complications and side effects (369) 369
expression (368) 368
research article (368) 368
protein kinase inhibitors - adverse effects (359) 359
pharmacokinetics (351) 351
in-vitro (341) 341
survival (334) 334
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6894) 6894
German (36) 36
French (29) 29
Russian (18) 18
Spanish (8) 8
Hungarian (6) 6
Polish (6) 6
Chinese (3) 3
Danish (3) 3
Dutch (3) 3
Turkish (3) 3
Italian (2) 2
Japanese (2) 2
Portuguese (2) 2
Swedish (2) 2
Czech (1) 1
Korean (1) 1
Norwegian (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1029 - 1035
Journal Article
Cancer, ISSN 0008-543X, 08/2010, Volume 116, Issue 15, pp. 3692 - 3701
Journal Article
Cancer, ISSN 0008-543X, 08/2010, Volume 116, Issue 16, pp. 3852 - 3861
Journal Article
Journal Article
JAMA, ISSN 0098-7484, 03/2012, Volume 307, Issue 12, pp. 1265 - 1272
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1175 - 1182
Journal Article
Circulation, ISSN 0009-7322, 03/2013, Volume 127, Issue 10, pp. 1128 - 1138
Journal Article
Annals of Surgery, ISSN 0003-4932, 09/2013, Volume 258, Issue 3, pp. 422 - 428
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 09/2007, Volume 110, Issue 6, pp. 1295 - 1302
BACKGROUND. Lonafarnib is an orally bioavailable nonpetidomimetic farnesyl transferase inhibitor with significant activity against BCR-ABL-positive cell lines... 
imatinib | chronic myeloid leukemia | phase 1 study | farnesyl transferase inhibitor | lonafarnib | Farnesyl transferase inhibitor | Imatinib | Phase 1 study | Chronic myeloid leukemia | Lonafarnib | CHRONIC MYELOGENOUS LEUKEMIA | MOLECULAR RESPONSES | KINASE INHIBITOR | DASATINIB BMS-354825 | PROTEIN TRANSFERASE | INTERFERON-ALPHA | IN-VITRO | ONCOLOGY | CHROMOSOME-POSITIVE LEUKEMIAS | CLINICAL ACTIVITY | Piperazines - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Pyridines - pharmacokinetics | Male | Fatigue - chemically induced | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Pyridines - adverse effects | Treatment Failure | Adult | Female | Piperidines - pharmacokinetics | Piperazines - pharmacokinetics | Piperidines - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Pyrimidines - administration & dosage | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Benzamides | Complications and side effects | Chemotherapy, Combination | Patient outcomes | Genetic aspects | Dosage and administration | Research | Drug therapy
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2006, Volume 354, Issue 24, pp. 2531 - 2541
Journal Article
Journal of Neurochemistry, ISSN 0022-3042, 09/2007, Volume 102, Issue 6, pp. 1749 - 1757
Imatinib, a protein tyrosine kinase inhibitor, may prevent the growth of glioblastoma cells. Unfortunately, its brain distribution is restricted by... 
CGP74588 | mouse | p‐glycoprotein | imatinib | blood–brain barrier | breast cancer resistance protein | Imatinib | Blood-brain barrier | Mouse | Breast cancer resistance protein | p-glycoproteinz | blood-brain barrier | CELLS | BIOCHEMISTRY & MOLECULAR BIOLOGY | p-glycoprotein | C-KIT | DRUG-RESISTANCE | DEFICIENT MICE | GF120918 | NEUROSCIENCES | REVERSAL | IN-VITRO | PHARMACOKINETICS | TYROSINE KINASE INHIBITOR | MULTIDRUG-RESISTANCE | Male | Piperazines - metabolism | Cyclosporins - pharmacology | Pyrimidines - metabolism | Quinolines - pharmacology | Antineoplastic Agents - metabolism | Brain - metabolism | Dose-Response Relationship, Drug | Brain - blood supply | ATP Binding Cassette Transporter, Subfamily B, Member 1 | ATP-Binding Cassette Transporters - genetics | Biological Transport, Active - physiology | ATP-Binding Cassette Transporters - metabolism | Dibenzocycloheptenes - pharmacology | ATP Binding Cassette Transporter, Subfamily B - genetics | Piperazines - pharmacokinetics | Immunosuppressive Agents - pharmacology | ATP Binding Cassette Transporter, Subfamily G, Member 2 | Tetrahydroisoquinolines - pharmacology | Biological Transport, Active - drug effects | Enzyme Inhibitors - pharmacology | Blood-Brain Barrier - drug effects | Imatinib Mesylate | ATP Binding Cassette Transporter, Subfamily B - metabolism | Blood-Brain Barrier - metabolism | Mice, Knockout | Brain - drug effects | Animals | ATP Binding Cassette Transporter, Subfamily B - antagonists & inhibitors | Acridines - pharmacology | Pyrimidines - pharmacokinetics | Mice | Benzamides | ATP-Binding Cassette Transporters - antagonists & inhibitors | Physiological aspects | Breast cancer | Proteins | Neurosciences | Inhibitor drugs | Rodents | Biochemistry | Glycoproteins
Journal Article